2,251 results match your criteria Neuro-Oncology[Journal]


Increased Risk of Pseudoprogression among Pediatric Low-Grade Glioma Patients Treated with Proton versus Photon Radiotherapy.

Neuro Oncol 2019 Feb 7. Epub 2019 Feb 7.

Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Background: Pseudoprogression (PsP) is a recognized phenomenon after radiotherapy (RT) for high-grade glioma, but is poorly characterized for low-grade glioma (LGG). We sought to characterize PsP for pediatric LGG patients treated with RT, with particular focus on the role of RT modality using photon-based intensity-modulated RT (IMRT) or proton beam therapy (PBT).

Methods: Serial MRI scans from 83 pediatric LGG patients managed at two institutions between 1998 and 2017 were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz042DOI Listing
February 2019

Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning.

Neuro Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Cognitive Neuropsychology, Tilburg University, The Netherlands.

Background: Meningioma patients are known to face cognitive deficits before and after surgery. We examined individual changes in cognitive performance over time and identified preoperative predictors of cognitive functioning 12 months after surgery in a large sample of meningioma patients.

Methods: Patients underwent neuropsychological assessment (NPA) using CNS Vital Signs 1 day before (T0), and 3 (T3) and 12 (T12) months after surgery. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz039DOI Listing
February 2019
3 Reads

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

Neuro Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland.

Background: Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC in HLA-A2 + glioma patients.

Methods: Adult patients with newly diagnosed glioblastoma (n=16) and grade III astrocytoma (n=3) were treated with radiochemotherapy followed by IMA950/poly-ICLC vaccination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz040DOI Listing
February 2019
2 Reads
5.562 Impact Factor

The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.

Neuro Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Neuropathology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.

Background: SND1 upregulation is a common phenomenon in different human malignant tissues. However, little information is available on the underlying mechanisms through which SND1 affects glioma cell proliferation and invasion.

Methods: SND1, RHOA and MKI67 were analysed in 187 gliomas by immunostaining. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz038DOI Listing
February 2019
5.562 Impact Factor

Prospective, Longitudinal Comparison of Neurocognitive Change in Pediatric Brain Tumor Patients Treated with Proton Radiotherapy versus Surgery Only.

Neuro Oncol 2019 Feb 7. Epub 2019 Feb 7.

Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.

Background: Proton radiotherapy (PRT) reduces the volume of normal tissue receiving radiation dose, which may lead to better neurocognitive outcomes. We examined change in neurocognitive scores over time in pediatric brain tumor patients treated with proton craniospinal irradiation (CSI), proton focal RT, or surgery only.

Methods: Patients received annual neurocognitive evaluations for up to 6 years. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz041DOI Listing
February 2019
2 Reads

Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.

Neuro Oncol 2019 Feb 8. Epub 2019 Feb 8.

Center for Neuro-Oncology, Dana-Farber Cancer Institute.

The finding that most grade II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and CDKN2A/B deletional analysis. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz033DOI Listing
February 2019
1 Read

Septal Dysembryoplastic Neuroepithelial Tumor: A Comprehensive Clinical, Imaging, Histopathologic and Molecular Analysis.

Neuro Oncol 2019 Feb 6. Epub 2019 Feb 6.

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Background: Dysembryoplastic neuroepithelial tumors (DNETs) are uncommon neural tumors presenting most often in children and young adults and associated with intractable seizures. Rare midline neoplasms with similar histological features to those found in DNETs have been described near the septum pellucidum and termed 'DNET-like neoplasms of the septum pellucidum'. Due to their rarity, these tumors have been described in just a few reports and their genetic alterations sought only in small series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz037DOI Listing
February 2019
1 Read

Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.

Neuro Oncol 2019 Feb 6. Epub 2019 Feb 6.

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.

Background: Patients with breast cancer positive for human epidermal growth factor receptor 2 (HER2) remain at high risk of intracranial relapse following treatment and experience increased rates of intracranial failure after stereotactic radiosurgery (SRS). We hypothesized that the addition of concurrent lapatinib to SRS would improve intracranial complete response rates.

Methods: Patients with newly diagnosed HER2-amplified breast cancer brain metastases from 2005-2014 who underwent SRS were included and divided into 2 cohorts based on timing of treatment with lapatinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz006DOI Listing
February 2019
2 Reads

Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.

Neuro Oncol 2019 Feb 6. Epub 2019 Feb 6.

Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN, USA.

Background: Codeletion of chromosome arms 1p and 19q (1p/19q codeletion) highly benefit diagnosis and prognosis in gliomas. In this study, we investigated the effect of 1p/19q codeletion on cancer-cell metabolism and evaluated possible metabolic targets for tailored therapies.

Methods: We combined in vivo 1H magnetic resonance spectroscopy (MRS) measurements in human gliomas with the analysis of a series of standard amino acids by liquid chromatography-mass spectroscopy (LC-MS) in human glioma biopsies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz031DOI Listing
February 2019
2 Reads

Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas.

Neuro Oncol 2019 Feb 5. Epub 2019 Feb 5.

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA.

Background: Neurofibromatosis type 1 (NF1) is a tumor-predisposition disorder caused by germline mutations in NF1. NF1 patients have an 8-16% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST), a highly-aggressive soft-tissue sarcoma, often arising from pre-existing benign plexiform neurofibromas (PN) and atypical neurofibromas (ANF). ANF are distinct from both PN and MPNST, representing an intermediate step in malignant transformation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz028DOI Listing
February 2019
3 Reads

TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.

Neuro Oncol 2019 Feb 5. Epub 2019 Feb 5.

UMR 1023, IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Univsité Paris Sud, CNRS, Université Paris-Saclay, Orsay, France.

Background: Glioblastoma is the most devastating brain tumor. Despite the use of multimodal treatments, most patients relapse, often due to the highly invasive nature of gliomas. However, the detection of glioma infiltration remains challenging. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz029DOI Listing
February 2019
5 Reads

A Low Percentage of Metastases in Deep Brain and Temporal Lobe Structures.

Neuro Oncol 2019 Jan 23. Epub 2019 Jan 23.

Department of Radiology Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA.

Background: Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized BMs are not evenly distributed across the brain and that several additional areas may be avoided in WBRT based on a low risk of developing a BM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz023DOI Listing
January 2019

The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility, and a revised proposal.

Neuro Oncol 2019 Jan 23. Epub 2019 Jan 23.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

Background: A scorecard to evaluate magnetic resonance imaging (MRI) findings during the course of leptomeningeal metastases (LM) has been proposed by the Response Assessment in Neuro-Oncology (RANO) group.

Methods: To explore the feasibility of the LANO scorecard, cerebrospinal MRI of 22 patients with LM from solid tumors were scored by 10 neuro-oncologists and 9 neuroradiologists at baseline and at follow-up after treatment. Raters were blinded for clinical data including treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz024DOI Listing
January 2019
1 Read
5.562 Impact Factor

Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster.

Neuro Oncol 2019 Jan 23. Epub 2019 Jan 23.

Institute of Neuropathology, University Hospital Münster, Münster, Germany.

Background: Recurrent specific mutations in evolutionarily conserved Histone 3 (H3) variants drive pediatric high-grade gliomas (HGG), but little is known about their downstream effects. The aim of this study was to identify genes involved in the detrimental effects of mutant H3.3-K27M, the main genetic driver in lethal midline HGG, in a transgenic Drosophila model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz021DOI Listing
January 2019

Diet and risk of glioma: combined analysis of three large prospective studies in the UK and USA.

Neuro Oncol 2019 Jan 23. Epub 2019 Jan 23.

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford.

Background: Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimise possible differential dietary recall between those with and without glioma, we present findings from three large prospective studies.

Methods: Participants included 692,176 from (UK) Million Women Study, 470,780 from (US) NIH-AARP Study, and 99,148 from (US) PLCO Study. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz013DOI Listing
January 2019
1 Read

Corrigendum.

Authors:

Neuro Oncol 2019 Jan 28. Epub 2019 Jan 28.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy203DOI Listing
January 2019

Accelerated progression of IDH mutant glioma after first recurrence.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Translational Neuro-Oncology Laboratory, Massachusetts General Hospital.

Background: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in WHO 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas.

Methods: We retrospectively analyzed 275 IDH mutant glioma patients treated at our institution. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz016DOI Listing
January 2019
3 Reads

Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-Based Classification.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Background: A feature of glioblastoma (GBM) is cellular and molecular heterogeneity, both within and between tumors. This variability causes a risk for sampling bias and potential tumor escape from future targeted therapy. Heterogeneous intra-tumor gene expression in GBM is well documented, but little is known regarding the epigenetic heterogeneity. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz011DOI Listing
January 2019
5 Reads

Liquid biopsy in Central Nervous System metastases: a RANO review and proposals for clinical applications.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy.

Liquid biopsies collect and analyze tumor components in body fluids, and there is an increasing interest in the investigation of liquid biopsies as a surrogate for tumor tissue in the management of both primary and secondary brain tumors. Herein we critically review available literature on spinal fluid and plasma circulating tumor cells (CTCs) and cell-free tumor (ctDNA) for diagnosis and monitoring of leptomeningeal and parenchymal brain metastases. We discuss technical issues and propose several potential applications of liquid biopsies in different clinical settings, i. Read More

View Article

Download full-text PDF

Source
http://fdslive.oup.com/www.oup.com/pdf/production_in_progres
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz012DOI Listing
January 2019
4 Reads

Modulation of temozolomide dose differentially affects T cell response to immune checkpoint inhibition.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Preston A. Wells Jr. Center for Brain Tumor Therapy UF Brain Tumor Immunotherapy Program Lillian S. Wells Department of Neurosurgery University of Florida Gainesville, FL.

Background: The changes induced in host immunity and the tumor microenvironment by chemotherapy have been shown to impact immunotherapy response in both a positive and negative fashion. Temozolomide is the most common chemotherapy used to treat glioblastoma (GBM) and has been shown to have variable effects on immune response to immunotherapy. Therefore, we aimed to determine the immune modulatory effects of temozolomide that would impact response to immune checkpoint inhibition in the treatment of experimental GBM. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz015DOI Listing
January 2019
4 Reads

Guiding the First Biopsy in Glioma Patients using Estimated Ki67 Maps Derived from Magnetic Resonance Imaging: Conventional versus Advanced Imaging.

Neuro Oncol 2019 Jan 17. Epub 2019 Jan 17.

Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center.

Background: Undersampling of gliomas at first biopsy is a major clinical problem, as accurate grading determines all subsequent treatment. We submit a technological solution to reduce the problem of undersampling by estimating a marker of tumor proliferation (Ki67) using MR imaging data as inputs, against a stereotactic histopathology gold standard.

Methods: MR imaging was performed with anatomic, diffusion, permeability and perfusion sequences, in untreated glioma patients in a prospective clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz004DOI Listing
January 2019
2 Reads

Brain and central nervous system tumor statistics: access to accurate data for all countries is critical!

Neuro Oncol 2019 Jan 14. Epub 2019 Jan 14.

Case Comprehensive Cancer Center and Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy205DOI Listing
January 2019
1 Read

Imaging and diagnostic advances for intracranial meningiomas.

Neuro Oncol 2019 Jan;21(Supplement_1):i44-i61

Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

The archetypal imaging characteristics of meningiomas are among the most stereotypic of all central nervous system (CNS) tumors. In the era of plain film and ventriculography, imaging was only performed if a mass was suspected, and their results were more suggestive than definitive. Following more than a century of technological development, we can now rely on imaging to non-invasively diagnose meningioma with great confidence and precisely delineate the locations of these tumors relative to their surrounding structures to inform treatment planning. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article/21/Supplemen
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347083PMC
January 2019
6 Reads

Molecular and translational advances in meningiomas.

Neuro Oncol 2019 Jan;21(Supplement_1):i4-i17

Division of Neurosurgery, University Health Network, University of Toronto, Ontario, Canada.

Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article/21/Supplemen
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347079PMC
January 2019
5 Reads

Advances in multidisciplinary therapy for meningiomas.

Neuro Oncol 2019 Jan;21(Supplement_1):i18-i31

Department of Neurological Surgery, University of California, San Francisco, California, USA.

Surgery has long been established as the first-line treatment for the majority of symptomatic and enlarging meningiomas, and evidence for its success is derived from retrospective case series. Despite surgical resection, a subset of meningiomas display aggressive behavior with early recurrences that are difficult to treat. The decision to radically resect meningiomas and involved structures is balanced against the risk for neurological injury in patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347080PMC
January 2019

Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.

Neuro Oncol 2019 Jan;21(Supplement_1):i32-i43

Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Background: Few studies have evaluated the health-related quality of life (HRQoL) of patients with meningiomas. Here, we report the largest prospective, longitudinal cross-sectional cohort study of HRQoL in meningiomas to date, in order to identify possible actionable determinants of global HRQoL.

Methods: Adults who had undergone resection of a grade I intracranial meningioma and were in routine follow-up at a single large tertiary center underwent HRQoL assessment using the QLQ-C30 questionnaire administered opportunistically at follow-up visits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347082PMC
January 2019
2 Reads
5.562 Impact Factor

Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas.

Neuro Oncol 2019 Jan;21(Supplement_1):i2-i3

Division of Neurosurgery, University Health Network, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347075PMC
January 2019

Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013.

Neuro Oncol 2019 Jan 12. Epub 2019 Jan 12.

School of Public Health, University of Alberta, Edmonton, Alberta, Canada.

Background: We present a national surveillance report on malignant primary brain and other central nervous system (CNS) tumors diagnosed in the Canadian population in 2009-2013.

Methods: Patients were identified through the Canadian Cancer Registry, an administrative dataset that includes cancer incidence data from all provinces/territories in Canada. Tumor types were classified by site and histology using the definitions from the Central Brain Tumor Registry of the United States (CBTRUS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy195DOI Listing
January 2019
1 Read

Trajectories of psychosocial and cognitive functioning in pediatric patients with brain tumors treated with radiation therapy.

Neuro Oncol 2019 Jan 8. Epub 2019 Jan 8.

Department of Radiation Oncology, St. Jude Children's Research Hospital.

Background: Pediatric patients with brain tumors who are treated with radiation therapy (RT) are at risk for neurocognitive and psychosocial late effects. Research to date has primarily examined these outcomes at a group level and in isolation. Advanced statistical techniques allow for person-centered analyses, as well as examination of relationships between domain-specific trajectories. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz010DOI Listing
January 2019
4 Reads

Using germline variants to estimate glioma and subtype risks.

Neuro Oncol 2019 Jan 8. Epub 2019 Jan 8.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Background: Twenty-five single nucleotide polymorphisms (SNPs) are associated with glioma risk. We hypothesized that the inclusion of these 25 SNPs with age at diagnosis and sex could predict risk of glioma as well as identify glioma subtypes.

Methods: Case-control design and multinomial logistic regression were used to develop models to estimate the risk of glioma development while accounting for histologic and molecular subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz009DOI Listing
January 2019
3 Reads

Radiation-induced astrocyte senescence is rescued by Δ133p53.

Neuro Oncol 2019 Jan 4. Epub 2019 Jan 4.

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Background: Cellular senescence and the senescence-associated secretory phenotype (SASP) contribute to the development of radiation therapy-associated side effects in the lung and blood vessels by promoting chronic inflammation. In the brain, inflammation contributes to the development of neurologic disease including Alzheimer's disease. In this study, we investigated the roles of cellular senescence and 133p53, an inhibitory isoform of p53, in radiation-induced brain injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz001DOI Listing
January 2019

Preclinical Assessment of MEK1/2 Inhibitors for Neurofibromatosis Type 2-Associated Schwannomas Reveal Differences in Efficacy and Drug Resistance Development.

Neuro Oncol 2019 Jan 6. Epub 2019 Jan 6.

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida.

Background: Neurofibromatosis type 2 (NF2) is a genetic tumor-predisposition disorder caused by NF2/merlin tumor suppressor gene inactivation. The hallmark of NF2 is formation of bilateral vestibular schwannomas (VS). Because merlin modulates activity of the Ras/Raf/MEK/ERK pathway, we investigated repurposing drugs targeting MEK1/2 as a treatment for NF2-associated schwannomas. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz002DOI Listing
January 2019
6 Reads
5.562 Impact Factor

Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.

Neuro Oncol 2019 Jan 6. Epub 2019 Jan 6.

Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.

Background: Meningioma is the most common intracranial tumor in the US and its etiology remains poorly understood. Meningioma has been predominantly studied among white populations. The aim of this study was to evaluate the associations of anthropometric, comorbidity, and hormonal factors with meningioma in an ethnically diverse population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz005DOI Listing
January 2019
1 Read

PET Imaging in Patients with Brain Metastasis - Report of the RANO/PET Group.

Neuro Oncol 2019 Jan 5. Epub 2019 Jan 5.

Dept. of Neurosurgery, Ludwig Maximilians-University of Munich, Munich, Germany.

Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz003DOI Listing
January 2019
4 Reads

A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.

Authors:
Howard Colman

Neuro Oncol 2019 Jan;21(1):6-7

Huntsman Cancer Institute and Department of Neurosurgery, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy190DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303428PMC
January 2019

ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1.

Neuro Oncol 2018 Dec 24. Epub 2018 Dec 24.

Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province, China.

Background: pithelial cell transforming sequence 2 (ECT2) is up-regulated in glioma and promotes glioma cell proliferation. A preliminary experiment showed a positive correlation between ECT2 and Pituitary tumor-transforming 1 (PTTG1). The aim of this study was to explore how ECT2 affects PTTG1 to influence the proliferation of glioma cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy207DOI Listing
December 2018

A Non-Hierarchical Organisation of Tumorigenic NG2 Cells in Glioblastoma promoted by EGFR.

Neuro Oncol 2018 Dec 22. Epub 2018 Dec 22.

Brain Repair Centre, University of Cambridge, UK.

Background: Expression of NG2 identifies an aggressive malignant phenotype in glioblastoma (GBM). Mouse models have implicated NG2 in the genesis, evolution and maintenance of glial cancers, and have highlighted potential interactions between NG2 and EGFR. However, it is unknown whether the lineage relationship of NG2+ and NG2- cells follows a hierarchical or stochastic mode of growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy204DOI Listing
December 2018
1 Read

Characterization of single microvesicles in plasma from glioblastoma patients.

Neuro Oncol 2018 Dec 17. Epub 2018 Dec 17.

Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, Massachusetts.

Background: Extracellular vesicles (EV) are shed by tumor cells but little is known about their individual molecular phenotypes and heterogeneity. While exosomes have received considerable attention, much less is known about larger microvesicles. Here we profile single microvesicles (MV) and exosomes from glioblastoma (GB) cells and MV from the plasma of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy187DOI Listing
December 2018
5 Reads

Old meet new-the path to combination treatments in pediatric low-grade gliomas.

Neuro Oncol 2018 Dec 11. Epub 2018 Dec 11.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy188DOI Listing
December 2018

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.

Neuro Oncol 2018 Nov 30. Epub 2018 Nov 30.

Kurume University School of Medicine, Fukuoka, Japan.

Background: We conducted a phase III trial of personalized peptide vaccination (PPV) for human leucocyte antigen (HLA)-A24+ recurrent glioblastoma to develop a new treatment modality.

Methods: We randomly assigned 88 recurrent glioblastoma patients to receive PPV (n=58) or the placebo (n=30) at a 2-to-1 ratio. Four of 12 warehouse peptides selected based on preexisting peptide-specific IgG levels or the corresponding placebos were injected 1/week for 12 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy200DOI Listing
November 2018
2 Reads

Financially Effective Test-Algorithm to Identify an Aggressive, EGFR-amplified Variant of IDH-Wildtype, Lower-Grade Diffuse Glioma.

Neuro Oncol 2018 Nov 28. Epub 2018 Nov 28.

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Background: cIMPACT-NOW update 3 recognizes amplification of EGFR as one important aberration in diffuse gliomas (WHO grade II/III). While these recommendations endorse testing, a cost-effective, clinically relevant testing paradigm is currently lacking. Here, we use real-world clinical data to propose a financially effective diagnostic test-algorithm in the context of new guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy201DOI Listing
November 2018
5 Reads

Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging.

Neuro Oncol 2018 Nov 28. Epub 2018 Nov 28.

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße, Hamburg, Germany.

Background: To determine the value of diffusion-weighted (DW) magnetic resonance imaging (MRI) for characterization of benign and malignant peripheral nerve sheath tumors (PNSTs) in patients with neurofibromatosis type 1 (NF1).

Methods: Twenty-six patients with NF1 and suspicion of malignant transformation of PNSTs were prospectively enrolled, and underwent DW MRI at 3T. For a set of benign (n=55) and malignant (n=12) PNSTs, functional MRI parameters were derived from both biexponential intravoxel incoherent motion (diffusion coefficient D and perfusion fraction f) and monoexponential data analysis (apparent diffusion coefficients (ADCs)). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy199DOI Listing
November 2018
1 Read

Disparities along the glioblastoma clinical trials landscape.

Neuro Oncol 2018 Nov 26. Epub 2018 Nov 26.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy176DOI Listing
November 2018

Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma.

Neuro Oncol 2018 Nov 10. Epub 2018 Nov 10.

Radiation Oncology, Beaumont Health, Royal Oak, MI, USA.

Background: Although considerable progress has been made in understanding molecular alterations driving gliomagenesis, the diverse metabolic programs contributing towards the aggressive phenotype of glioblastoma remain unclear. The aim of this study was to define and provide molecular context to metabolic reprogramming driving gliomagenesis.

Methods: Integrative cross-platform analyses coupling global metabolomic profiling with genomics in patient-derived glioma (low-grade astrocytoma [LGA; n=28] and glioblastoma [n=80]) was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy185DOI Listing
November 2018
1 Read

CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.

Neuro Oncol 2019 Jan;21(1):139-141

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière?Charles Foix, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303433PMC
January 2019
3 Reads

Corrigendum.

Neuro Oncol 2018 Nov 20. Epub 2018 Nov 20.

Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO l'Hospitalet, IDIBELL, Barcelona, Spain, Hospitalet de Llobregat, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy179DOI Listing
November 2018

Corrigendum.

Authors:

Neuro Oncol 2018 Nov 17. Epub 2018 Nov 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy171DOI Listing
November 2018

Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma.

Neuro Oncol 2018 Nov 19. Epub 2018 Nov 19.

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

Background: The goal of this study was to evaluate outcomes in children with relapsed, molecularly-characterized intracranial ependymoma treated with or without craniospinal irradiation (CSI) as part of a course of repeat radiation therapy (re-RT).

Methods: This was a retrospective cohort study of 31 children. Patients with distant relapse received CSI as part of re-RT. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy191DOI Listing
November 2018
7 Reads